Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

NCT06904300 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Gastric (Cardia, Body) Cancer

Interventions

DRUG: AK112 + paclitaxel
DRUG: Paclitaxel ± ramucirumab

Sponsor

Sun Yat-sen University